Biotech - Spark Newswire

1 minute read

Protagonist Therapeutics Highlights Presentation Of Phase 2 Rusfertide Data At European Hematology Association 2021 Virtual Congress.

Today, 8:08 PM

Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced updated results from the ongoing Phase 2 study of rusfertide, an investigational new drug being evaluated

PTGX

4 minute read

FDA
News

Equillium Reports Topline Results From EQUATE Study In First-Line Treatment Of Acute Graft-Versus-Host Disease

By Benzinga Newsdesk

Today, 8:08 PM

Itolizumab continues to demonstrate favorable safety and efficacy profile Rapid and durable responses resulted in clinically meaningful reduction in corticosteroid use Data support clinical advancement of itolizumab in

5 minute read

Curis Highlights Presentation Of Data From Ongoing Phase 1/2 Study Of CA-4948 At European Hematology Association 2021 Virtual Congress

By Bill Haddad

Today, 8:08 PM

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced updated data from its ongoing Phase 1/2 open-label, single arm, dose

CRIS

1 minute read

Precigen Stock Surges On Positive AG019 Data for Chronic Treatment Of Type 1 Diabetes

By Vandana Singh

Today, 8:08 PM

Precigen Inc’s (NASDAQ:PGEN) subsidiary Precigen ActoBio announced topline results from the Phase 1b/2a study evaluating AG019 ActoBiotics to treat recent-onset type…

PGEN

1 minute read

European Medicines Agency Gives Update On Evaluation Of COVID-19 Vaccine Plus Myocarditis, Pericarditis Cases: Notes Cases Of Myocarditis And/Or Pericarditis Were Also Reported In Europe Following Vaccination With All COVID-19 Vaccines

By Benzinga Newsdesk

Today, 8:08 PM

-Reuters

BNTX

1 minute read

FDA
News

Brazilian Health Regulator, Anvisa, Approves Use Of Pfizer COVID-19 Vaccine For Children 12+

By Benzinga Newsdesk

Today, 8:08 PM

-Reuters

EWZ

3 minute read

FDA
News

Novan Reports Topline Results From Pivotal Phase 3 Trial Of SB206 In Patients With Molluscum Contagiosum: Achieves Statistical Significance, No Serious Adverse Events Reported

By Benzinga Newsdesk

Today, 8:08 PM

– B-SIMPLE4 achieves statistical significance for the primary endpoint with p-value less than 0.0001 – – No serious adverse events related to treatment with SB206 – – Novan intends to

NOVN

3 minute read

FDA
News

Mustang Bio Offers Interim Phase 1/2 Data For MB-106 CD20-Targeted CAR T In Patients With Relapsed, Refractory B-Cell Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia: 93% overall response rate and 67% complete response rate

By Benzinga Newsdesk

Today, 8:08 PM

Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity 93% overall response rate and 67% complete response rate in patients treated

MBIO

1 minute read

Despite Hitting Mid-Stage Trial Endpoint Goal, Vertex Strikes Out Rare Lung Disease Candidate; Stock Tumbles

By Vandana Singh

Today, 8:08 PM

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced the Phase 2 data evaluating VX-864 in alpha-1 antitrypsin deficiency (AATD) with the PiZZ genotype.

VRTX

2 minute read

FDA
News

Editas Medicine Highlights Presentation Of Preclinical Data Supporting Initiation Of EDIT-301 Phase 1/2 RUBY Trial For Treatment Of Sickle Cell Disease At European Hematology Association Congress

By Benzinga Newsdesk

Today, 8:08 PM

Preclinical data demonstrated robust fetal hemoglobin (HbF) induction in erythroid progeny cells with no detection of off-target editing; cells showed reduced sickling and improved rheological behavior RUBY trial of

EDIT